Drug ID: 3d00000002
Drug Name: Cabazitaxel
Generic Names: Jevtana
Legal Status: Non Opioid Prescription only drug
Indication for Mother: Category D
There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Recommended Dose: Dose is based on Body Surface Area (BSA) of the individual.
The recommended dose is 25 mg/m² as a one-hour intravenous infusion every three weeks in combination with oral prednisone 10 mg.
Recommended In: This medication is an antineoplastic agent, prescribed for prostate cancer with prednisone. It slows or stops the growth of cancer cells.
Directions For Use: It comes as a solution for injection to be administered by a trained healthcare provider into the vein.
Storage: Store it at room temperature (25°C), and in an airtight container.
Dosage Forms: Intravenous Injection
Side Effects: Blood - Anemia, abnormal decrease in white blood cells and platelets.
Heart - Abnormal heart rhythm and low blood pressure.
Gastrointestinal - Diarrhea, nausea, vomiting, constipation, abdominal pain, and indigestion.
General - Fatigue, weakness, fever, swelling in the extremities, throat inflammation and generalized pain.
Infections - Urinary tract infections.
Metabolic - Loss of appetite, dehydration and decrease in weight.
Musculoskeletal - Back pain, joint pain and muscle spasms.
Central Nervous System - Nerve disease, sensory loss, dizziness, and headache.
Genitourinary - Blood in urine and painful urination.
Respiratory - Difficulty in breathing and cough.
Skin - Hair loss.
In Case of Overdose: There is no known antidote for Cabazitaxel overdose. Anticipated complications of overdose include exacerbation of adverse reactions such as bone marrow suppression and gastrointestinal disorders.
In case of overdose, the patient should be kept in a specialized unit where vital signs, chemistry and particular functions can be closely monitored. Patients should receive therapeutic G-CSF as soon as possible after discovery of overdose. Other appropriate symptomatic measures should be taken, as needed.
Avoid If: Caution should be exercised in patients with history of bone marrow depression, poor immunity, decrease in white blood cells, dehydration, kidney or liver disease, infection, stomach problem, any allergy, who are taking other medications, elderly, children, during pregnancy and breastfeeding.
It may cause dizziness, do not drive a car or operate machinery while taking this medication.
Avoid contact with people who have infections.
It may reduce platelet counts; avoid injury or bruising.
Patient may develop with increased risk of kidney damage with the following symptoms: decreased amount of urine, swelling of the face or body. If it is so consult with your doctor.
Avoid live vaccination during the treatment period.
Monitor complete blood counts regularly while taking this medication.
Contraindicated in patients with severe decrease in white blood cells, and hypersensitivity.
Drug Interaction: Some products that may interact with this drug include: other drugs that can cause bleeding/bruising (including antiplatelet drugs such as clopidogrel, NSAIDs such as ibuprofen/naproxen, "blood thinners" such as warfarin/dabigatran).
Aspirin can increase the risk of bleeding when used with this medication. However, if your doctor has directed you to take low-dose aspirin for heart attack or stroke prevention (usually at dosages of 81-325 milligrams a day), you should continue taking it unless your doctor instructs you otherwise. Ask your doctor or pharmacist for more details.
Other medications can affect the removal of cabazitaxel from your body, which may affect how cabazitaxel works. Examples include azole antifungals (such as itraconazole), macrolide antibiotics (such as clarithromycin), HIV protease inhibitors (such as ritonavir), nefazodone, rifamycins (such as rifabutin), St. John's wort, drugs used to treat seizures (such as carbamazepine, phenytoin, phenobarbital), among others.